Kendle Reports 78% Drop in Profits, Begins Cost-Saving Efforts

Thursday, May 7, 2009 07:00 AM

Cincinnati-based contract research organization (CRO) Kendle warned investors earlier this month that first quarter 2009 profits would be down, and down they are.

The company reported net income of $886,000 or $0.06 per share for the first quarter 2009, compared with net income of $4.1 million or $0.27 per diluted share for the same period last year. Net service revenues for the quarter totaled $108.1 million, compared with $1.14 million in the first quarter 2008.

Kendle chairman and CEO Candace Kendle warned shareholders earlier this month that first quarter revenues would be significantly lower than original forecasts. That news caused the company’s shares to plummet more than 50%. Following the company’s earnings release yesterday, Kendle’s share price increased in after-hours trading by half a percentage point to $9.61.

To cut costs, Kendle has implemented strict controls over discretionary spending, a hiring and wage freeze and “workforce optimization initiatives.”  The company said it plans to reorganize its leadership structure, ultimately saving between $17.5 million and $22.5 million in the second half of 2009.

“We are taking aggressive steps to enhance our business development efforts, realign our leadership and organizational structure and implement a series of margin improvement and cost reduction initiatives to move our business to the next level,” Kendle said in a company statement.

Senior vice president and chief financial officer (CFO) and secretary Karl “Buzz” Brenkert III abruptly left the CRO last week, after six years as CFO. He was replaced by Kendle’s vice president of accounting Keith Cheesman.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs